Found 10 matching trials
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma PHASE1 The purpose of this study is to assess the safety, pharmacokinetic, pharmac...
Show More Location
Henan Provincial Oncology Hospital
Learn More & Join Trial
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors PHASE1 APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising dru...
Show More Location
The First Affiliated Hospital of Sun Yat-Sen University
Learn More & Join Trial
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer PHASE1 This is a multi-center, open-label, phase Ib/II study of combination therap...
Show More Location
BRCR Medical Center
Learn More & Join Trial
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors PHASE1 APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising dru...
Show More Learn More & Join Trial
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy PHASE1 The study is a designed to evaluate safety and activity of APG-1252 when ad...
Show More Location
Banner MD Anderson Cancer Center
Learn More & Join Trial
APG-1252 in Patients With SCLC or Advanced Solid Tumors PHASE1 APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising dru...
Show More Location
Guangdong General Hospital
Learn More & Join Trial
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients PHASE1 There are unmet medical needs in patients who resist to EGFR TKIs, especial...
Show More Status
Active Not Recruiting
Location
Sun-Yat Sen University Cancer Center
Learn More & Join Trial
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia PHASE1 To find safe and effective doses of lisaftoclax and pelcitoclax in combinat...
Show More Location
Multiple Locations
Learn More & Join Trial
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers PHASE1 This phase I trial tests the safety, side effects, and best dose of combina...
Show More Status
Active Not Recruiting
Location
Emory University Hospital/Winship Cancer Institute
Learn More & Join Trial
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML PHASE1 This is a phase Ib/II study that aims to investigate the safety, tolerabili...
Show More Learn More & Join Trial